Venetoclax monotherapy appears to improve outcomes in some patients with acute
myelogenous leukemia (AML), according to a phase 2, single-arm study.
"This study included patients that
were in categories that are difficult to treat - relapsed, refractory, and/or
elderly and deemed medically unfit to receive induction therapy," Dr.
Anthony Letai from Dana-Farber Cancer Institute in Boston told Reuters Health
"The fact that some of these
patients had leukemias that were relapsed or refractory to very tough regimens,
including regimens that require multi-week inpatient hospital stays, but
nonetheless responded to an oral outpatient therapy taken once a day was a very
interesting result," he said.
The following is an introduction to the recent article from
“The Scientist” magazine. This article Shepherds in, a landmark event in the
annals of the medical achievements of Man.
Most of my students have heard my lectures on “Our Current
Definitions of Good Health”, and what changed in the twentieth century to
double Man’s “Life Expectancy”.
Realize that Life Expectancy is not the same number we use for “The LifeSpan of Man”, but the two measurements continue to move together in
In 2011, the scientific community changed “The Life Span of
Man” from one hundred years (where it has always been) to one hundred thirty
The Science Advisory Board is a reputable peer reviewed scientific publication I recommend to all of my students. If you want to keep abreast of the latest in science, become a member. I will always have these updates available to my readers. Coming soon is my article on the new CPR guidelines and the need for everyone to possess the knowledge to save a life.
Thu, Jul21, 2011 8:17 am